A decade of tamoxifen reduces BCa recurrence
Doubling the duration of adjuvant tamoxifen treatment in women estrogen receptor (ER)-positive breast cancer reduces risk of late recurrence and death compared with the current standard-of-care of 5 years' therapy. So say the results of a large international randomized trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium and simultaneously published in The Lancet.
Reduced subsequent births reported after severe maternal morbidity
November 26th 2024Women experiencing severe maternal morbidity during their first pregnancy face significantly lower odds of subsequent births, emphasizing the need for personalized reproductive counseling and ongoing monitoring.
Read More
Maternal sFLT1 and EDN1 linked to late-onset preeclampsia
November 25th 2024A new study highlights the association of maternal soluble Fms-like tyrosine kinase 1 and endothelin 1 with preeclampsia severity, offering insights into the pathogenesis of early- and late-onset forms of the condition.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
